Please login to the form below
Aliqopa
This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.
Novartis considers filings for PI3K drug in breast cancer
years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers.
Latest news
-
Bayer bags speedy US approval for lymphoma drug Aliqopa
Bayer bags speedy US approval for lymphoma drug Aliqopa. FDA decision sets the pharma firm up for a showdown with Gilead's Zydelig. ... The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Medical Writers Required - Hertfordshire
-
Competitive
-
Systematic Review Lead- London
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Senior Medical Writer
-
Salary is DOE
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Manager
-
Negotiable
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Associate Scientific Director
-
Salary TBC
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
Cello Health Insight
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
